Diagnostics and treatment of polymyalgia rheumatica

被引:5
|
作者
Dejaco, C. [1 ]
Matteson, E. L. [2 ,3 ,4 ,5 ]
Buttgereit, F. [6 ]
机构
[1] Med Univ Graz, Klin Abt Rheumatol, Graz, Austria
[2] Mayo Clin, Div Rheumatol, Dept Internal Med, Coll Med, Rochester, MN USA
[3] Mayo Clin, Div Epidemiol, Dept Internal Med, Coll Med, Rochester, MN USA
[4] Mayo Clin, Div Rheumatol, Dept Hlth Sci Res, Coll Med, Rochester, MN USA
[5] Mayo Clin, Div Epidemiol, Dept Hlth Sci Res, Coll Med, Rochester, MN USA
[6] Charite, Med Klin Schwerpunkt Rheumatol & Klin Immunol, Charitepl 1, D-10117 Berlin, Germany
来源
ZEITSCHRIFT FUR RHEUMATOLOGIE | 2016年 / 75卷 / 07期
关键词
Epidemiology; Treatment; Monitoring; Arthritis; Autoimmune diseases; GIANT-CELL ARTERITIS; PROVISIONAL CLASSIFICATION CRITERIA; TERM-FOLLOW-UP; RHEUMATISM/AMERICAN COLLEGE; EUROPEAN LEAGUE; DOUBLE-BLIND; GLUCOCORTICOID THERAPY; 2015; RECOMMENDATIONS; ONSET; METHOTREXATE;
D O I
10.1007/s00393-016-0105-3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Polymyalgia rheumatica (PMR) is the most common autoimmune inflammatory disease in older persons with an average age of onset of 73 years. Typical symptoms include acute or subacute bilateral shoulder pain with severe stiffness and often neck and bilateral hip pain. Giant cell arteritis (GCA) occurs in approximately 20 % of cases and up to two thirds of patients with GCA have symptoms of PMR. There are many disease which mimic PMR, elderly onset rheumatoid arthritis is frequently misdiagnosed as PMR. Although there are no specific laboratory tests, CaEuroreactive protein and erythrocyte sedimentation rates are elevated in over 90 % of patients. The diagnosis may be aided by imaging, especially ultrasonography and magnetic resonance imaging (MRI). Treatment currently consists of glucocorticoids at an initial dose of 12.5-25 mg prednisone equivalent daily. Treatment duration is typically 2aEuro3 years but may be longer. Under certain conditions low-dose methotrexate can be used as adjuvant therapy.
引用
收藏
页码:687 / 700
页数:14
相关论文
共 50 条
  • [21] Differential diagnostics of polymyalgia rheumatica in a university hospital in Finland
    Paltta, J.
    Suuronen, S.
    Pirila, L.
    Palomaki, A.
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2023, 52 (06) : 689 - 695
  • [22] DIFFERENTIAL DIAGNOSTICS OF POLYMYALGIA RHEUMATICA IN A UNIVERSITY HOSPITAL IN FINLAND
    Paltta, J.
    Suuronen, S.
    Pirila, L.
    Palomaki, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 1031 - 1032
  • [23] Treatment of Polymyalgia Rheumatica A Systematic Review
    Hernandez-Rodriguez, Jose
    Cid, Maria C.
    Lopez-Soto, Alfons
    Espigol-Frigole, Georgina
    Bosch, Xavier
    ARCHIVES OF INTERNAL MEDICINE, 2009, 169 (20) : 1839 - 1850
  • [24] Polymyalgia rheumatica after pembrolizumab treatment
    Ramirez-Poza, Silvia
    Pardo-Cabello, Alfredo Jose
    Salvatierra, Y. Juan
    MEDICINA CLINICA, 2023, 161 (06): : 270 - 271
  • [25] Pulse steroid treatment of polymyalgia rheumatica
    Cimmo, MA
    Macchioni, P
    Boiardi, L
    Cantini, F
    Pulsatelli, L
    Salvarani, C
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2004, 22 (03) : 381 - 382
  • [26] DURATION OF STEROID TREATMENT IN POLYMYALGIA RHEUMATICA
    Tang, E.
    Shah, P.
    McKenna, F.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 793 - 793
  • [27] Assessment of treatment efficacy in polymyalgia rheumatica
    Arends, Suzanne
    van der Geest, Kornelis S. M.
    Sandovici, Maria
    LANCET RHEUMATOLOGY, 2023, 5 (04): : E171 - E173
  • [28] Current diagnosis and treatment of polymyalgia rheumatica
    De Bandt, Michel
    JOINT BONE SPINE, 2014, 81 (03) : 203 - 208
  • [29] Polymyalgia rheumatica
    Kermani, Tanaz A.
    Warrington, Kenneth J.
    LANCET, 2013, 381 (9860): : 63 - 72
  • [30] Polymyalgia rheumatica
    Gonzalez-Gay, Miguel A.
    Matteson, Eric L.
    Castaneda, Santos
    LANCET, 2017, 390 (10103): : 1700 - 1712